SCHEMBL21551433

SCHEMBL21551433

CC(C)(C)OC(=O)N1CCN(c2ncc(Oc3cc(C(=O)O)cc(-c4cc(Cl)cc(Cl)c4)c3)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.48
▸ CKS1B P61024 2/20 0.41
▸ SKP1 P63208 2/20 0.41
▸ SKP2 Q13309 2/20 0.41
▸ PTPN11 Q06124 1/20 0.41
▸ MAPT P10636 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ GBA1 P04062 1/20 0.39
▸ FURIN P09958 1/20 0.39
▸ ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29891027 0.86 GPR119 (0.52) GPR119CKS1BSKP1SKP2PTPN11
SCHEMBL21550983 0.86 GPR119 (0.52) GPR119CKS1BSKP1SKP2PTPN11
SCHEMBL28548738 0.86 GPR119 (0.52) GPR119CKS1BSKP1SKP2PTPN11
SCHEMBL26077384 0.83 ALDH1A1 (0.41) FURIN
SCHEMBL21551682 0.82 GPR119 (0.54) GPR119
SCHEMBL21551056 0.80 GPR119 (0.48) GPR119CKS1BSKP1SKP2
SCHEMBL30931823 0.80 GPR119 (0.48) GPR119CKS1BSKP1SKP2
SCHEMBL29891232 0.80 GPR119 (0.48) GPR119CKS1BSKP1SKP2
SCHEMBL3605523 0.78 GPR119 (0.59) GPR119CKS1BSKP1SKP2PTPN11
SCHEMBL30931826 0.77 GPR119 (0.53) GPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384509-B Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-04-30 — — CN disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 — — EP disclosed
CN-112384509-A Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 — — CN disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 — — WO disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 GPR119 2318/4885CKS1B 713/4885SKP1 931/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 GPR119 2318/4885CKS1B 713/4885SKP1 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback